PharVision Advisers’s Taylor Morrison TMHC Stock Holding History

PharVision Advisers’s Portfolio TMHC Stock Details TMHC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,601	Closed	-$216K	–	427
2025 Q1	$216K	Buy	+3,601	New	+$224K	0.3%	177

Other funds holding TMHC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DSC

Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return

LPC

Long Pond Capital New York $1.05B AUM 16.49% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PharVision Advisers's TMHC Position: Q2 2025 in Review

PharVision Advisers sold out of Taylor Morrison (TMHC) in Q2 2025, closing a stake of 3,601 shares — an estimated $216K sold.

PharVision Advisers first reported a position in TMHC in Q1 2025 and held it in 1 quarter. The position peaked at $216K in Q1 2025. 436 funds tracked by Wall St. Rank hold TMHC as of Q2 2025.

PharVision Advisers reported no remaining Taylor Morrison position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 3,601 Taylor Morrison shares in Q2 2025, an estimated $216K.
PharVision Advisers first reported a position in Taylor Morrison in Q1 2025 and held it in 1 quarter.
PharVision Advisers's Taylor Morrison position peaked at $216K in Q1 2025.
436 funds tracked by Wall St. Rank held Taylor Morrison as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.